Method for Predicting the Response of a Subject with an Autoimmune Disease to a B Cell-Targeting Therapy
AssigneeUCL Business PLC
InventorGeraldine Cambridge
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for predicting the response of a subject with an autoimmune disease to a B cell-targeting therapy. In particular, the invention relates to predicting the response of a patient by analysing the level of soluble CD23 (sCD23) and B cell activation factor (BAFF) in a sample from said subject. The B cell-targeting therapy can be an anti-CD20 antibody. The autoimmune disease can be systemic lupus erythematosus (SLE). Methods of treatment, compositions and kits are disclosed.
Claims23
A method for predicting the response of a subject with an autoimmune disease to a B cell-targeting therapy, wherein said method comprises analysing the level of soluble CD23 and B cell activation factor (BAFF) in a sample from said subject.
Use of soluble CD23 and BAFF as biomarkers for predicting the response of a subject with an autoimmune disease to a B cell-targeting therapy.
The method or use according to any preceding claim wherein said method or use identifies a subject suitable for treatment with a B cell-targeting therapy.
The method or use according to any preceding claim comprising determining the polypeptide level of soluble CD23 and BAFF.
The method or use according to any preceding claim, wherein the sample is a blood sample.
The method or use according to any preceding claim, wherein the subject is human.
The method or use according to any preceding claim, wherein the B cell-targeting therapy is an anti-CD20 antibody.
A method of treating an autoimmune disease in a subject predicted to have an improved response to a B cell-targeting therapy by the method according to any preceding claim, comprising administering a therapeutically effective amount of a B cell-targeting therapy to the subject.
A composition comprising a therapeutically effective amount of a B cell-targeting therapy for use in the treatment of an autoimmune disease in a subject predicted to have an improved response to a B cell-targeting therapy by the method according to any preceding claim.
A kit for predicting the response to a B cell-targeting therapy of a subject with an autoimmune disease, wherein the kit comprises one or more agents capable of determining the level of soluble CD23 and BAFF in a sample from the subject, wherein the kit optionally comprises a set of instructions.
A method, use, composition for use or kit substantially as described herein and with reference to the accompanying Examples.
Dependencies are inferred from the claim text.